Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 160

1.

Immunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis.

Pham NA, Schwock J, Iakovlev V, Pond G, Hedley DW, Tsao MS.

BMC Cancer. 2008 Feb 6;8:43. doi: 10.1186/1471-2407-8-43.

2.

Localization of the human hedgehog-interacting protein (Hip) in the normal and diseased pancreas.

Kayed H, Kleeff J, Esposito I, Giese T, Keleg S, Giese N, Büchler MW, Friess H.

Mol Carcinog. 2005 Apr;42(4):183-92.

PMID:
15754313
3.
4.

Gamma-aminobutyric acid (GABA) stimulates pancreatic cancer growth through overexpressing GABAA receptor pi subunit.

Takehara A, Hosokawa M, Eguchi H, Ohigashi H, Ishikawa O, Nakamura Y, Nakagawa H.

Cancer Res. 2007 Oct 15;67(20):9704-12.

6.

Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.

Xue A, Xue M, Jackson C, Smith RC.

Int J Biochem Cell Biol. 2009 Aug-Sep;41(8-9):1731-8. doi: 10.1016/j.biocel.2009.03.004. Epub 2009 Mar 21.

PMID:
19433314
7.

Increased expression of valosin-containing protein (p97) is associated with lymph node metastasis and prognosis of pancreatic ductal adenocarcinoma.

Yamamoto S, Tomita Y, Hoshida Y, Nagano H, Dono K, Umeshita K, Sakon M, Ishikawa O, Ohigashi H, Nakamori S, Monden M, Aozasa K.

Ann Surg Oncol. 2004 Feb;11(2):165-72.

PMID:
14761919
8.

Comparative proteomic analysis for the detection of biomarkers in pancreatic ductal adenocarcinomas.

Qi T, Han J, Cui Y, Zong M, Liu X, Zhu B.

J Clin Pathol. 2008 Jan;61(1):49-58. Epub 2007 Apr 5.

PMID:
17412869
9.

Actinin-4 expression in primary and metastasized pancreatic ductal adenocarcinoma.

Welsch T, Keleg S, Bergmann F, Bauer S, Hinz U, Schmidt J.

Pancreas. 2009 Nov;38(8):968-76. doi: 10.1097/MPA.0b013e3181b28d6f.

PMID:
19672209
10.

Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma.

Yamamoto S, Tomita Y, Hoshida Y, Morooka T, Nagano H, Dono K, Umeshita K, Sakon M, Ishikawa O, Ohigashi H, Nakamori S, Monden M, Aozasa K.

Clin Cancer Res. 2004 Apr 15;10(8):2846-50.

11.

[Expression of sonic hedgehog, EGFR and PCNA proteins in pancreatic cancer and their correlations to cell proliferation].

Hu WG, Wang CY, Liu T, Xiong JX, Yang ZY.

Ai Zheng. 2007 Sep;26(9):947-51. Chinese.

PMID:
17927850
12.

Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.

Xue A, Scarlett CJ, Jackson CJ, Allen BJ, Smith RC.

Pancreas. 2008 Mar;36(2):160-7. doi: 10.1097/MPA.0b013e31815750f0.

PMID:
18376307
13.

Proteomic analysis to identify biomarker proteins in pancreatic ductal adenocarcinoma.

Chung JC, Oh MJ, Choi SH, Bae CD.

ANZ J Surg. 2008 Apr;78(4):245-51. doi: 10.1111/j.1445-2197.2008.04429.x.

PMID:
18366394
14.

Decreased expression and promoter methylation of the menin tumor suppressor in pancreatic ductal adenocarcinoma.

Cavallari I, Silic-Benussi M, Rende F, Martines A, Fogar P, Basso D, Vella MD, Pedrazzoli S, Herman JG, Chieco-Bianchi L, Esposito G, Ciminale V, D'Agostino DM.

Genes Chromosomes Cancer. 2009 May;48(5):383-96. doi: 10.1002/gcc.20650.

PMID:
19170121
15.

High TRAIL death receptor 4 and decoy receptor 2 expression correlates with significant cell death in pancreatic ductal adenocarcinoma patients.

Sanlioglu AD, Dirice E, Elpek O, Korcum AF, Ozdogan M, Suleymanlar I, Balci MK, Griffith TS, Sanlioglu S.

Pancreas. 2009 Mar;38(2):154-60. doi: 10.1097/MPA.0b013e31818db9e3.

PMID:
18981952
16.

Loss of ONECUT1 expression in human pancreatic cancer cells.

Jiang X, Zhang W, Kayed H, Zheng P, Giese NA, Friess H, Kleeff J.

Oncol Rep. 2008 Jan;19(1):157-63.

PMID:
18097590
17.

Prognostic significance of maspin in pancreatic ductal adenocarcinoma: tissue microarray analysis of 223 surgically resected cases.

Cao D, Zhang Q, Wu LS, Salaria SN, Winter JW, Hruban RH, Goggins MS, Abbruzzese JL, Maitra A, Ho L.

Mod Pathol. 2007 May;20(5):570-8. Epub 2007 Mar 30.

18.

Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas.

Mees ST, Mardin WA, Sielker S, Willscher E, Senninger N, Schleicher C, Colombo-Benkmann M, Haier J.

Ann Surg Oncol. 2009 Aug;16(8):2339-50. doi: 10.1245/s10434-009-0531-4. Epub 2009 May 28.

PMID:
19475450
19.

Glucagon/insulin ratio as a potential biomarker for pancreatic cancer in patients with new-onset diabetes mellitus.

Kolb A, Rieder S, Born D, Giese NA, Giese T, Rudofsky G, Werner J, Büchler MW, Friess H, Esposito I, Kleeff J.

Cancer Biol Ther. 2009 Aug;8(16):1527-33. Epub 2009 Aug 13.

PMID:
19571666
20.

The ubiquitin-proteasome pathway mediates gelsolin protein downregulation in pancreatic cancer.

Ni XG, Zhou L, Wang GQ, Liu SM, Bai XF, Liu F, Peppelenbosch MP, Zhao P.

Mol Med. 2008 Sep-Oct;14(9-10):582-9. doi: 10.2119/2008-00020.Ni.

Supplemental Content

Support Center